dapagliflozin


( Last Updated : November 1, 2021)
Generic Name:
dapagliflozin
Project Status:
Not filed
Therapeutic Area:
Chronic kidney disease
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Forxiga
Project Line:
Reimbursement Review
Project Number:
N/A

Details


Submission Type:
Non Submission
Indications:
To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer